BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Grants Alpharma (ALO) Final Approval And First-To-File Status For Gabapentin Tablets


10/19/2005 5:11:54 PM

FORT LEE, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Alpharma Inc. today announced that Purepac Pharmaceutical Co., a subsidiary of Alpharma, has received final approval from the United States Food and Drug Administration ("FDA") for gabapentin tablets, 600 mg and 800 mg. The FDA also awarded the company first-to-file status and 180-day market exclusivity for these tablets. Alpharma's gabapentin tablets, to be marketed under the Purepac® brand, are the generic equivalent of Neurontin® brand tablets, marketed by Pfizer. Neurontin® tablets had brand sales of over $700 million in 2003 and is indicated as adjunctive therapy in the treatment of partial seizures of epilepsy and post-herpetic neuralgia. The company is not commenting on launch plans at this time.

Neurontin ® is a registered trademark of the Warner Lambert Company.

Alpharma press releases are also available at our website: http://www.alpharma.com.

Alpharma Inc. (NYSE: ALO - News) is a global generic pharmaceutical company with leadership positions in products for humans and animals. Uniquely positioned to expand internationally, Alpharma is presently active in more than 60 countries. Alpharma is a leading manufacturer of generic pharmaceutical products in the U.S., offering solid, liquid and topical pharmaceuticals. It is also one of the largest suppliers of generic solid dose pharmaceuticals in Europe, with a growing presence in Southeast Asia. Alpharma is among the world's leading producers of several important pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry, swine and cattle.

Source: Alpharma Inc.



Read at Reuters
Read at BioSpace.com

   
Epilepsy

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES